Quanterix Enters into a License Agreement that Grants Abbott Access to Portfolio of Bead-Based Technology Patents for Use in In Vitro Diagnostics

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into a non-exclusive royalty-bearing license agreement with Abbott Laboratories (NYSE: ABT), the global healthcare company. The non-exclusive license grants Abbott access to Quanterix’ portfolio of bead-based technology patents for use in in vitro diagnostic (IVD) applications.

Under the terms of the agreement, Quanterix will receive an initial license fee, milestone fees subject to the achievement by Abbott of future development, regulatory, and launch milestones and royalties on the sale of licensed products. To learn more about Quanterix, click here.

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from

Read More

Point of Care (PoC) Molecular Diagnostics Market Is Booming

Point of Care (PoC) Molecular Diagnostics Market

Global Point of Care (PoC) Molecular Diagnostics Market 2020-2030 by Product (Assays, Instruments, Software), Technology (PCR, INAAT, Microarray), Application, End User, and Region: Trend Forecast and Growth Opportunity , Covid 19 Outbreak Impact research report added by Report Ocean, is an in-depth analysis of market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider Point of Care (PoC) Molecular Diagnostics market, and compares it with other markets., market definition, regional market opportunity, sales and revenue by region, manufacturing cost analysis, Industrial Chain, market effect factors analysis, Point of Care (PoC) Molecular Diagnostics market size forecast, market data & Graphs and Statistics, Tables, Bar &Pie Charts, and many more for business intelligence. Get

Read More

Influenza Diagnostics Market Size and Share 2020 Trends, Future Demands, Growth Factors, Emerging Technologies, Global Industry Forecast to 2023

The MarketWatch News Department was not involved in the creation of this content.

Sep 25, 2020 (The Expresswire) —
“Influenza Diagnostics Market”research provides actionable intelligence on major parameters impacting the market, analyses the market performance of key companies, market dynamics of key segments, outlines the market performance across global regions. The insights of the industry over the past 5 years and a forecast until 2023 is provided.

Influenza diagnostic kits are available in both rapid and conventional testing models. These kits can detect influenza virus strains in swab samples collected from the nasal, nasopharyngeal, or oropharyngeal region. Our influenza diagnostics market analysis considers sales from point-of-care testing, immunodiagnostics, and molecular diagnostics kits segments to end-user sectors such as hospitals and diagnostic laboratories, academic and research institutions, and home care. Our analysis also considers the sales of influenza diagnostics in Asia, Europe, North America, and ROW. In 2018, the point-of-care testing

Read More

Point of Care Molecular Diagnostics Market revenue to cross USD 2.8 Bn by 2026: Global Market Insights, Inc.

Major point of care (PoC) molecular diagnostics market players include Bio-Rad Laboratories, Abbott Laboratories, Sysmex, Danaher, Vircell.

Selbyville, Delaware, Sept. 21, 2020 (GLOBE NEWSWIRE) —

According to latest report “PoC Molecular Diagnostics Market by Technology (PCR, In Situ Hybridization, Sequencing, Isothermal Amplification), Application (Infectious Disease, {Flu, Respiratory Syncytial Virus (RSV), Tuberculosis (TB), HIV, Gonorrhea, Chlamydia, Hepatitis C, Hepatitis B}, Oncology, Hematology), End-use (Hospitals, Clinics), Regional Outlook, Price Trends, Competitive Market Share & Forecast 2026”, by Global Market Insights, Inc., the market valuation of point of care (PoC) molecular diagnostics will cross $2.8 billion by 2026. Strategic initiatives for developing innovative PoC molecular diagnostics assays and instruments will accelerate the market growth.

Point of care molecular diagnostics tests deliver several benefits from enhancing patient care to limiting healthcare expenditure. High-quality diagnostic tests are widely available in developed countries, while developing economies face a shortage of high-quality diagnostic tools. Therefore, there

Read More